Shop
QualityLab ResultsPartner
Log In
BPC-157 — research-grade lyophilized peptide vial from Peptide.Express, ≥99% HPLC purity
Expand Image
≥99% PurityUS SynthesizedIn Stock

BPC-157 — Body Protection Compound-157 | Synthetic 15-Amino Acid Gastric Pentadecapeptide

Research-Grade Compound

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a protein sequence found in human gastric juice. Amino acid sequence: GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). Molecular formula C62H98N16O22, molecular weight 1,419.5 Da, CAS 137525-51-0.

Select Size

$40.00$80.00USD / Unit
1
HPLC Verified
Same Day Shipping
BPC-157 + TB-500 Wolverine Stack research guide →

In-depth research overview, mechanism of action, and study applications.

No variant-specific CoA for 10mg — showing product CoA
Certificate Details
Purity≥99%
Methodology
HPLCLC-MS/MS
CAS Number137525-51-0
Molecular FormulaC62H98N16O22
Molecular Weight1419.5 g/mol
SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (pentadecapeptide)
Verify Results with Testing Laboratory
Download PDFOpen in New TabVerify with Lab

This Certificate of Analysis was issued by an independent third-party laboratory. Peptide.Express does not conduct in-house testing. Results are provided as-is from the testing facility and confirm batch identity, purity, and analytical methodology. For questions about specific CoA results, contact [email protected].

≥99% by HPLCLC-MS/MS VerifiedCoA Every BatchIn-Vitro Research Use Only

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a protein sequence found in human gastric juice. Amino acid sequence: GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). Molecular formula C62H98N16O22, molecular weight 1,419.5 Da, CAS 137525-51-0.

The gastric origin is not incidental. BPC-157's strongest and most replicated preclinical evidence involves gastrointestinal mucosal protection and gut lining repair — which is where the parent protein sits in the first place. The musculoskeletal work came later and is now the larger body of literature, but the gut data is the older and more consistent of the two.

BPC-157 does not occur naturally as a standalone peptide. It is a synthetic fragment designed for research, and the full-length parent protein it derives from has itself not been characterized in the depth the fragment has. Over 100 preclinical studies have examined its effects on tendon, ligament, muscle and gastrointestinal tissue; almost all of them are rodent models.

How Does BPC-157 Work? Mechanism of Action

The primary mechanism is upregulation of VEGF (vascular endothelial growth factor) expression, promoting angiogenesis at the site of injury. New vasculature is the rate-limiting step in delivering nutrients and repair-mediating cells to damaged tissue, which is why this single mechanism accounts for so much of the observed effect across otherwise unrelated injury models.

BPC-157 also activates focal adhesion kinase (FAK) and paxillin. These are the signaling proteins that govern how a cell grips its substrate and whether it can move across it. FAK activation accelerates fibroblast migration into wound beds and influences the alignment of newly deposited collagen fibers — in tendon models, fiber organization matters as much as fiber quantity for tensile strength recovery.

A third arm runs through the nitric oxide synthase pathway. BPC-157 interacts with NO-system signaling in a way that appears to underlie much of its anti-inflammatory activity and its counter-regulation of NSAID-induced gastric damage in rodent models.

What the evidence does not establish: a receptor. Despite the volume of preclinical work, no BPC-157 receptor has been identified. The mechanisms above are downstream observations, not a binding story. Researchers designing mechanistic studies should be explicit about that gap rather than treating VEGF upregulation as a proximal event.

Research Applications of BPC-157

Musculoskeletal Repair Models

  • Tendon-to-bone healing: rat rotator cuff and Achilles models are the standard preparation, with tensile strength recovery as the primary endpoint.
  • Ligament and muscle crush injury: fibroblast migration and collagen fiber organization are measured alongside gross healing metrics.
  • Angiogenesis quantification: VEGF expression and capillary density in the repair zone are the mechanistic readouts that link BPC-157 to the healing outcome.

Gastrointestinal and Mucosal Research

  • NSAID-induced ulceration models: BPC-157 is studied as a counter-agent in rodent preparations where gastric damage is chemically induced.
  • Inflammatory bowel models: mucosal cell survival signaling and local angiogenesis restoration are the endpoints of interest.
  • Intestinal anastomosis and fistula healing: several of the older Croatian research group papers focus here, and these are among the more replicated findings.

Combination and Comparative Pharmacology

  • BPC-157 vs TB-500: separating local VEGF-driven repair from systemic actin-mediated cell migration requires both compounds in the same experimental design.
  • Wolverine Stack studies: the BPC-157 + TB-500 combination is studied as a complementary-mechanism model, though combination pharmacokinetic data does not exist.
  • Multi-component blends: BPC-157 is a component of both KLOW and Wolverine formulations.

BPC-157 vs TB-500

FeatureBPC-157TB-500
Full nameBody Protection Compound-157Synthetic Thymosin β-4
Amino acids15 (GEPPPGKPADDAGLV)43 (contains LKKTET motif)
Molecular weight1,419.5 Da4,963.4 Da
CAS number137525-51-077591-33-4
Primary mechanismVEGF-mediated local angiogenesisG-actin sequestration, cell migration
Scope of actionLargely local to the administration siteSystemic
Gastrointestinal evidenceStrong (gastric origin)Limited
Tendon / ligament evidenceStrongStrong
WADA statusProhibited at all timesProhibited at all times

These two are complementary rather than redundant, and that is the whole research argument for the Wolverine Stack. BPC-157 activates repair where it is placed; TB-500 recruits cells to that site from elsewhere. Different mechanisms, different scopes, different cell populations.

Read the full BPC-157 vs TB-500 comparison

BPC-157 Technical Specifications

Technical specifications for BPC-157, including molecular data, purity standard, testing methods and storage requirements.
Compound NameBPC-157 (Body Protection Compound-157)
Common SynonymsBPC157, PL 14736, pentadecapeptide BPC 157, Bepecin
Amino Acid SequenceGEPPPGKPADDAGLV
Amino Acid Count15 (pentadecapeptide)
CAS Number137525-51-0
Molecular FormulaC62H98N16O22
Molecular Weight1,419.5 Da
Purity≥99% by HPLC
Purity ConfirmationLC-MS/MS molecular weight verification
Endotoxin TestingLAL (Limulus Amebocyte Lysate) method
Physical FormLyophilized powder
AppearanceWhite to off-white powder
ReconstitutionBacteriostatic water or sterile 0.9% sodium chloride
Storage (lyophilized)-20°C, desiccated, protected from light
Storage (reconstituted)2–8°C, use within 14–28 days
Shelf Life24 months from manufacture (lyophilized)
Testing MethodsHPLC, LC-MS/MS, LAL Endotoxin
DocumentationCertificate of Analysis (CoA) per batch
WADA StatusProhibited at all times
FDA StatusNot approved for human use; not a scheduled substance
Intended UseIn-vitro laboratory research only

How to Reconstitute BPC-157 for Research

BPC-157 dissolves readily — it is one of the easier peptides in the catalog to reconstitute. If a vial resists dissolution after 90 seconds of swirling, that is worth noting on the batch record rather than escalating the agitation.

  1. Allow the vial to reach room temperature before opening.
  2. Draw the calculated volume of bacteriostatic water. For the 10 mg vial, 2 mL yields 5 mg/mL and 2.5 mL yields 4 mg/mL.
  3. Swab the vial septum with alcohol and allow 30 seconds to dry.
  4. Inject the diluent slowly against the inner vial wall, not onto the lyophilized cake.
  5. Swirl gently for 60–90 seconds until fully dissolved. Do not shake or vortex.
  6. Confirm the solution is clear and colorless. Discard if cloudy, discolored, or if particulate matter is present.
  7. Label with reconstitution date and concentration.
  8. Store at 2–8°C, use within 14–28 days, and avoid repeated freeze-thaw cycles.

Diluent: bacteriostatic water for peptide reconstitution. Full protocol: step-by-step peptide reconstitution guide. Concentration maths: peptide reconstitution calculator.

Frequently Asked Questions — BPC-157

What is BPC-157 used for in research?

BPC-157 is studied in preclinical tissue-repair models — tendon, ligament, muscle and gastrointestinal mucosa — where VEGF-mediated angiogenesis and focal adhesion kinase signaling are the mechanisms of interest. It is sold for in-vitro laboratory research use only.

What is BPC-157's amino acid sequence?

GEPPPGKPADDAGLV — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Fifteen residues, which is why it is described as a pentadecapeptide. Molecular formula C62H98N16O22, molecular weight 1,419.5 Da.

What is BPC-157 made from?

It is chemically synthesized, not extracted. The sequence corresponds to a partial region of a protein found in human gastric juice, but the research compound is produced by solid-phase peptide synthesis and does not come from a biological source.

How does BPC-157 promote healing in research models?

Primarily by upregulating VEGF expression, which drives new blood vessel formation at the injury site. It also activates focal adhesion kinase and paxillin, accelerating fibroblast migration and influencing collagen fiber organization, and interacts with the nitric oxide synthase pathway. No receptor has been identified — these are downstream observations rather than a binding mechanism.

Is BPC-157 the same as body protection compound?

BPC-157 is a 15-amino-acid fragment of BPC, the body protection compound found in gastric juice. They are not the same molecule — the fragment is what has been studied, and the full-length parent protein is far less characterized.

Is BPC-157 legal to purchase for research?

BPC-157 is not a scheduled substance in the United States and is legal to purchase for laboratory research. It is not FDA-approved for human use, and in 2023 the FDA placed it in Category 2 of its bulk drug substances review for compounding. Peptide.Express sells it strictly for in-vitro research.

Is BPC-157 WADA prohibited?

Yes. BPC-157 was added to the WADA Prohibited List under section S0 (non-approved substances) and is prohibited at all times, both in and out of competition.

What is the difference between BPC-157 and TB-500?

Scope and mechanism. BPC-157 is a 15-residue peptide that upregulates VEGF and acts largely at the site where it is placed. TB-500 is synthetic Thymosin β-4, roughly 3.5 times the molecular weight, and works by sequestering G-actin to enable cell migration throughout the system. They target different steps of the repair cascade.

Can BPC-157 be used orally in research models?

Oral administration appears in the rodent literature and BPC-157 is reported to be stable in human gastric juice, which is consistent with its origin. Whether oral bioavailability is meaningful at the systemic level is a separate and much less settled question — the oral data is thinner than the injected data.

What is the Wolverine Stack?

A research combination of BPC-157 and TB-500, named for the complementary repair mechanisms rather than any formal designation. Peptide.Express supplies it as the pre-blended Wolverine Blend and as a separate-vial kit. No published combination pharmacokinetic data exists.

How long does BPC-157 take to show effects in research models?

In rodent tendon and gastric injury preparations, measurable differences from control typically appear within 7–14 days, with tensile strength endpoints taking longer than histological or angiogenesis markers. Study design and injury model drive this far more than the compound does.

What purity standard does Peptide.Express use for BPC-157?

≥99% by reverse-phase HPLC, with LC-MS/MS confirming the 1,419.5 Da molecular weight. Every batch ships with a Certificate of Analysis showing the chromatogram, mass data, endotoxin result and batch identifier.

How should BPC-157 be stored?

Lyophilized at -20°C, desiccated and protected from light, stable for 24 months. Once reconstituted, at 2–8°C for 14–28 days. Do not freeze the reconstituted solution.

Where is the Certificate of Analysis for BPC-157?

On this page and in the Peptide.Express lab results library. Each CoA is batch-specific and lists HPLC purity, LC-MS/MS identity confirmation, endotoxin level, testing laboratory and test date.

Research References

  1. "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing." Biomolecules, 2025. Read the BPC-157 musculoskeletal healing narrative review on PMC
  2. Sikiric P, Boban Blagaic A, Strbe S, et al. "The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity." Pharmaceuticals, 2024. Read the Sikirić BPC-157 pleiotropic-activity review on PMC
  3. Staresinic M, Sebecic B, Patrlj L, et al. "Gastric Pentadecapeptide BPC 157 Accelerates Healing of Transected Rat Achilles Tendon and In Vitro Stimulates Tendocytes Growth." Journal of Orthopaedic Research, 2003. Read the BPC-157 rat Achilles tendon healing study on PubMed

All products are sold for in-vitro laboratory research use only. Not intended for human consumption, clinical use, or veterinary use. Peptide.Express makes no medical claims. Consult the published literature for research application guidance.

Further Reading

Related Research Compounds

TB-500The systemic cell-migration counterpart studied alongside BPC-157 in the Wolverine Stack.Wolverine BlendPre-blended BPC-157 + TB-500 in a single vial.KLOW BlendFour-peptide formulation containing BPC-157 alongside KPV, GHK-Cu and TB-500.BPC-157 + TB-500 KitSeparate vials for protocols that need independent control of each compound.